Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. Andriani F, Nan B, Yu J, Li X, Weigel NL, McPhaul MJ, Kasper S, Kagawa S, Fang B, Matusik RJ, Denner L, Marcelli M (2001) J Natl Cancer Inst 93: 1314-24 Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Buchanan G, Yang M, Harris JM, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, Greenberg NM, Tilley WD (2001) Mol Endocrinol 15: 46-56 A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo. Blobaum AL, Byers FW, Bridges TM, Locuson CW, Conn PJ, Lindsley CW, Daniels JS (2015) Drug Metab Dispos 43: 1718-26 Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. Lloyd A, Penson D, Dewilde S, Kleinman L (2008) Prostate Cancer Prostatic Dis 11: 153-9 Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, Penson D (2005) Urology 66: 835-9 Effects of flutamide and hydroxy-flutamide on the growth of human benign prostatic hyperplasia cells in primary culture: a preliminary report. Hallowes R, Cox S, Hayward S, Deshpande N, Towler J (1991) Anticancer Res 11: 1799-805
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.